Despite the fact that IL-1β is considered to be as important a cytokine as TNF-α at the onset of IBD, there are currently few specific antibodies against IL-1β tested in IBD with the exception of canakinumab [47]. This evidence concerns the gene TNF and inflammatory bowel disease.